A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs AC 0100MA (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 29 Sep 2017 Planned number of patients changed from 78 to 184.
- 06 Mar 2017 Status changed from not yet recruiting to recruiting.
- 02 Mar 2017 New trial record